Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium.
Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH; REAL-C Investigators. Huang CF, et al. Among authors: tanaka y. Hepatol Int. 2019 Sep;13(5):587-598. doi: 10.1007/s12072-019-09974-z. Epub 2019 Aug 28. Hepatol Int. 2019. PMID: 31463665
Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease.
Fujiwara K, Tanaka Y, Orito E, Ohno T, Kato T, Sugauchi F, Suzuki S, Hattori Y, Sakurai M, Hasegawa I, Ozasa T, Kanie F, Kano H, Ueda R, Mizokami M. Fujiwara K, et al. Among authors: tanaka y. J Gastroenterol Hepatol. 2004 Dec;19(12):1343-7. doi: 10.1111/j.1440-1746.2004.03439.x. J Gastroenterol Hepatol. 2004. PMID: 15610306
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Kurosaki M, et al. Among authors: tanaka y. J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19. J Hepatol. 2011. PMID: 21129805
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; Ochanomizu-Liver Conference Study Group. Sakamoto N, et al. Among authors: tanaka e, tanaka y. J Med Virol. 2011 May;83(5):871-8. doi: 10.1002/jmv.22038. Epub 2011 Feb 25. J Med Virol. 2011. PMID: 21360545
The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.
Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M. Ito K, et al. Among authors: tanaka y. J Clin Microbiol. 2011 May;49(5):1853-60. doi: 10.1128/JCM.02139-10. Epub 2011 Mar 9. J Clin Microbiol. 2011. PMID: 21389156 Free PMC article.
Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.
Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Matsuura K, et al. Among authors: tanaka y. Hepatol Res. 2011 Jun;41(6):505-11. doi: 10.1111/j.1872-034X.2011.00807.x. Epub 2011 May 18. Hepatol Res. 2011. PMID: 21585626
Favorable factors for re-treatment with pegylated interferon α2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus.
Tamori A, Kioka K, Kurai O, Sakaguchi H, Enomoto M, Fujii H, Kobayashi S, Iwai S, Morikawa H, Yamaguchi S, Kawasaki Y, Oka H, Tanaka Y, Kawada N. Tamori A, et al. Among authors: tanaka y. Hepatol Res. 2011 Dec;41(12):1169-77. doi: 10.1111/j.1872-034X.2011.00887.x. Epub 2011 Sep 26. Hepatol Res. 2011. PMID: 21951389
15,350 results
You have reached the last available page of results. Please see the User Guide for more information.